Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 3Phase 1/2 2Phase 1 2

Status

Active not recruiting 3Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Genitourinary 1

Conditions

Breast Neoplasms 2Prostatic Neoplasms 1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1

Interventions

pembrolizumab 64Carboplatin 63Paclitaxel 54Magnetic Resonance Spectroscopy 45Specimen Handling 43Cisplatin 43Gemcitabine 35Bevacizumab 31Docetaxel 30Doxorubicin 29Leucovorin 28Fluorouracil 27Dexamethasone 27Cyclophosphamide 26Pemetrexed 25Radiation 23Oxaliplatin 23Radiotherapy 22Etoposide 22durvalumab 21Nivolumab 21Letrozole 21Vincristine 20Rituximab 20Irinotecan 20Taxes 19Prednisone 19Capecitabine 19Lenalidomide 18130-nm albumin-bound paclitaxel 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Gonadotropin-Releasing Hormone × 30 days × Clear all
NCT02531516 2026-06-05

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Aragon Pharmaceuticals, Inc.

Phase 3 Active not recruiting
1,503 enrolled
Genitourinary

Prostatic Neoplasms

NCT06065748 2026-06-04

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Hoffmann-La Roche

Phase 3 Recruiting
1,050 enrolled
Breast

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT04961996 2026-05-22

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

Hoffmann-La Roche

Phase 3 Active not recruiting
4,170 enrolled
Breast

Breast Neoplasms

NCT04546009 2026-05-19

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

Hoffmann-La Roche

Phase 3 Active not recruiting
992 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡